Treatment of Tracheal Cancer in Adenoid Cystic Carcinoma with Low Disease Dynamics

This protocol addresses a specific presentation of advanced tracheal cancer: adenoid cystic carcinoma (ACC) of the trachea in the setting of low disease dynamics — where the slow pace of progression is the defining feature shaping the systemic treatment approach.

Clinical Scenario

Adenoid cystic carcinoma is one of the two most prevalent primary tracheal malignancies in adults, alongside squamous-cell carcinoma — together accounting for more than two-thirds of such cases. When ACC presents in the advanced setting with low disease dynamics, the indolent tempo of progression becomes the central determinant of treatment selection, distinguishing this scenario from more rapidly progressive disease.

Systemic Therapy Approach

For ACC of the trachea with low disease dynamics, the evidence-based strategy centres on a cytostatic approach — specifically, a single-agent chemotherapy regimen. The slow-growing biology of ACC and considerations around tolerability inform this direction.

Agent selection, sequencing criteria, and monitoring guidance are available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/or.2024.1451247

The most common types are squamous-cell carcinoma (SCC) and adenoid cystic carcinoma (ACC), which together account for more than two-thirds of primary tracheal tumors in adults.
Use cytostatic monotherapy for patients with ACC who have low disease dynamics [II, B].
In cases of low disease dynamics, cytostatic monotherapy can be implemented — with an expected response time of 5–20 months and an objective response rate of approximately 15%.
Monotherapy is reasonable given the slow dynamics of ACC and a more favorable safety profile.

View source ↗